ACXP Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -17.46%, SMA50 -36.18%, SMA200 -69.43%). The stock’s 14-day RSI is 27.12 (weak momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -92.19% below its high and over 16.31% above its low. Average 10-day trading volume of 59.48 thousand shares is below the 3-month average of 112.85 thousand, indicating normal recent market interest.

Acurx Pharmaceuticals, Inc. generated EPS of -$8.52 over the past year. Five-year average earnings growth is -7.84%. Wall Street analysts project EPS growth of 43.37% annually over the next five years. The latest quarter delivered EPS of -$0.53. The next quarter is forecast at -$1.01. Next year's EPS is expected at $15.27. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $31.00 to $31.00. The high target offers 2114.29% upside. The low target suggests 2114.29% downside. The mean target is $31.00. This offers 2114.29% upside. Acurx Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2026, missed forecasts by 40.71%. The prior quarter beat by 5.08%. Over the last six quarters, Apple has recorded several small beats. These include 1366.67% in May 12, 2025.

Acurx Pharmaceuticals, Inc. has 4.30 million shares outstanding. The public float is 5.14 million shares, elevated short interest at 2.26% of float. This equals 94.13 thousand shares. The short ratio is 0.76 days. Institutional investors hold 6.36% of the float. Insiders own 2.99%. LUCI DAVID P holds 49.26 thousand shares, DELUCCIA ROBERT J has 49.26 thousand shares and Scodari Joseph C has 24.63 thousand shares.

Acurx Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.35. This means the shares are trading below this model’s fair value.

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) closed at $1.40 USD, losing -$0.01 (-0.71%) from the previous close of $1.41. The stock is currently mid-range between its 52-week high and low $1.31 and $8.34. With a market capitalization of about $6.02 million, Acurx Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-2.02). Key stats such as the average daily volume over the past year has been around 123.83 thousand shares, volume is running light vs its 52-week average. Headquartered in Staten Island, NY, Acurx Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Luci, the company employs approximately 4 people and listed since June 25, 2021. Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections.

Acurx Pharmaceuticals, Inc. trades at a P/E ratio of -0.39, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.73 suggesting the stock is closer to book value. The P/FCF stands at -0.97, also above market averages.

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares are flat 2.41% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Acurx Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.39. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.00, suggesting 1042.86% upside. Our AI forecast model points to short-term weakness (-2.14% over two weeks), a medium-term fall (-67.14% over three months), and a longer-term loss (-91.43% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Acurx Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.14%, with price expected at $1.37 by September 24, 2026, within a range of $1.32 to $1.42 3-Month Outlook: Projected fall of -67.14%, reaching $0.46 by December 08, 2026, with a range of $0.08 to $0.86. 1-Year Outlook: Projected loss of -91.43%, with price at $0.12 by September 10, 2027, within a range of $0.00 to $1.32.